Oruka Therapeutics reported that its IL 23p19 inhibitor ORKA 001 achieved 63.5% complete skin clearance in a Phase 2a trial, outperforming Skyrizi's 47% and comparable to Bimzelx's ~59%. However, the 'once yearly' pitch obscures that patients require two injections in the first…
A biotech company called Oruka Therapeutics reported this week that its experimental psoriasis drug helped 63.5% of patients achieve complete skin clearance in a mid-stage trial — better numbers than the two drugs that currently dominate the market. The company is pitching its drug as a once-yearly option in a field where patients typically inject themselves every few weeks. The pitch sounds like a revolution. The math is less dramatic.
ORKA-001, Oruka's drug candidate, requires two injections in the first month, then one injection once a year thereafter, according to the company's investor relations press release. That works out to roughly 1,200 milligrams of drug delivered per year. AbbVie's Skyrizi — the market leader that posted 47% clearance in its pivotal trial — involves four clinic visits per year at half that annual dose: 600 milligrams, according to Skyrizi's prescribing information. Oruka is asking patients to come to the doctor once a year instead of four times, but it is asking them to put twice as much drug into their bodies each year.
The distinction matters because drug pricing in the United States often runs on a cost-per-milligram basis. Rebates, pharmacy benefit manager contracts, and hospital purchasing decisions can all shift depending on how much active ingredient a therapy delivers. A drug that requires fewer clinic visits may be more convenient, but if the annual milligram load is double that of an existing therapy, manufacturers face different variable cost pressures — and those pressures tend to show up in negotiations six to eighteen months after a launch.
"The real value proposition here is fewer patient encounters, not a lower drug burden," said one rheumatologist who reviewed the trial data at our request and asked not to be named because they had not seen the complete dataset. "The dose is meaningfully higher. Whether that's a clinical problem depends on long-term safety data we don't have yet."
The Phase 2a trial, called EVERLAST-A, enrolled 63 patients with moderate-to-severe plaque psoriasis and tested a single dose level of ORKA-001. The primary endpoint was the proportion of patients achieving PASI 100 — complete skin clearance — at week 16, according to Oruka's investor relations materials. That is a standard endpoint in psoriasis drug development and the same measure used in the trials that led to Skyrizi's approval in 2019 and Bimzelx's approval in 2021. ORKA-001's 63.5% clearance rate compares favorably to Skyrizi's 47% at the same timepoint, and to Bimzelx's roughly 59% at week 16, according to those drugs' approved labeling.
ORKA-001 is an antibody therapy — a protein designed to bind to and neutralize a specific biological target — targeting a pathway called IL-23p19. That is the same mechanism as Skyrizi, which targets the same pathway through a different binding site. The IL-23p19 inhibitor class is one of the most commercially successful in dermatology: Skyrizi generated $17.562 billion in global net revenues last year, AbbVie reported in its fourth-quarter 2025 earnings release. Bimzelx, from UCB, is the newer entrant and has been gaining share since its 2021 approval.
Oruka's half-life extension technology — the engineering that lets the drug persist in the bloodstream long enough to dose once yearly — is where the dosing math originates. The company says updated Phase 1 pharmacokinetic data support the once-yearly schedule, but those data are from early-stage testing in healthy volunteers, not from the Phase 2a trial currently generating the headline results, according to the company's press release. Phase 3 trials, which would test the dosing claim at scale in the patient population where it would eventually be prescribed, have not yet begun. The company says it is planning to initiate Phase 3.
The safety profile through week 16 was consistent with the IL-23p19 drug class broadly, according to Oruka's press release. No serious adverse events were reported in the trial, though the company has not yet published the full safety dataset in a peer-reviewed journal. The short-term picture looks clean; the long-term picture is what Phase 3 is designed to answer.
What Phase 3 will also answer — or at least generate data around — is whether the dosing arithmetic actually translates into the pricing and access dynamics Oruka is betting on. If payers calculate reimbursement on a cost-per-milligram basis, a 1,200-milligram annual dose commands a higher negotiated price than a 600-milligram one, all else being equal. Oruka would need to demonstrate that the convenience advantage — one visit versus four — is worth the higher milligram burden to the system, not just to the patient.
Oruka is a privately held company that has not yet disclosed pricing or launch timelines. It expects to present full Phase 2a data at a medical conference and submit the results for publication in a peer-reviewed journal, according to a spokesperson.
For patients with moderate to severe psoriasis, the drug class Oruka is entering has already transformed outcomes compared to older systemic therapies. Complete skin clearance was essentially unheard of in the pre-biologic era. Whether fewer annual injections plus double the annual milligram load adds up to a better option depends on questions that won't be answered until Phase 3 generates a year's worth of pharmacokinetic data — and until someone runs the numbers on what that dosing math actually costs at the pharmacy counter.